---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009247"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:39:32.265447+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harrow Q1 revenue $47.8M (+38% YoY); VEVYE revenue $21.5M (+35% QoQ); reaffirms >$280M FY2025 guidance

## Summary
- Revenues $47.8M, up 38% YoY; GAAP net loss $(17.8)M; adjusted EBITDA $(2.0)M.
- VEVYE revenue $21.5M (+35% QoQ); VAFA launch drove new RXs >4X and prescribers >4X at PhilRx.
- VEVYE new patent exp. 2042 added to Orange Book; second production site expected H1 2026.
- TRIESENCE received CMS pass-through status Apr 1; accounts ordering more than doubled since Jan.
- Refinancing $222.75M debt in active discussions; expect resolution by late summer/early fall.

## SEC filing metadata
- accession: 0001641172-25-009247
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000164117225009247/0001641172-25-009247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000164117225009247/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009247
- JSON: https://secwatch.observer/filing/0001641172-25-009247.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009247.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.